We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $2M invested in XTL Biopharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 2 → 4 (+2)

18% less capital invested

Capital invested by funds: $2.45M → $2M (-$452K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
+2
Holders Change %
+100%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$3.13K
2
TRCT
Tower Research Capital (TRC)
New York
+$737

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$2.03K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$1.79M -$2.03K -55 -0.1%
Invesco
2
Invesco
Georgia
$203K – – –
UBS Group
3
UBS Group
Switzerland
$3K +$3.13K +85 New
TRCT
4
Tower Research Capital (TRC)
New York
$1K +$737 +20 New

XTLB Hedge Fund Activity: Q3 2015 in Review

4 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2015, worth a combined $2M — down 18% from $2.45M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new XTLB positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $3.13K. The largest seller was Sabby Management, cutting an estimated $2.03K.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2015, up from 2 in Q2 2015.
  • Funds reported $2M of XTL Biopharmaceuticals stock for Q3 2015, down 18% quarter-over-quarter.
  • 2 funds opened new XTL Biopharmaceuticals positions in Q3 2015 and 0 closed out, a net change of +2 holders.
  • The largest XTL Biopharmaceuticals buyer in Q3 2015 was UBS Group, an estimated $3.13K added.
  • The largest XTL Biopharmaceuticals seller in Q3 2015 was Sabby Management, an estimated $2.03K sold.

Based on aggregated 13F filings for Q3 2015.